T
Tilman B. Drüeke
Researcher at French Institute of Health and Medical Research
Publications - 415
Citations - 22817
Tilman B. Drüeke is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Kidney disease & Hyperparathyroidism. The author has an hindex of 68, co-authored 413 publications receiving 21471 citations. Previous affiliations of Tilman B. Drüeke include Versailles Saint-Quentin-en-Yvelines University & University of Paris-Sud.
Papers
More filters
Journal Article
Abnormal parameters of acid-base balance in genetic hypertension.
Journal ArticleDOI
Morphological quantification of aortic calcification from low magnification images
TL;DR: The morphological image processing algorithms developed for the semi-automated measurement of calcification from sections of aorta stained using von Kossa’s silver nitrate procedure and acquired at low magnification power are presented.
Journal ArticleDOI
Intravenous Iron: How Much Is Too Much?
Tilman B. Drüeke,Ziad A. Massy +1 more
TL;DR: Anemia is associated with poor cardiovascular and global outcome in patients with chronic kidney disease (CKD) and the correction of anemia requires epoetin in most instances.
Journal ArticleDOI
Does the Administration of Sevelamer or Nicotinamide Modify Uremic Toxins or Endotoxemia in Chronic Hemodialysis Patients
Aurélie Lenglet,Nicolas Fabresse,Méline Taupin,Cathy Gomila,Sophie Liabeuf,Saïd Kamel,Jean-Claude Alvarez,Tilman B. Drüeke,Tilman B. Drüeke,Tilman B. Drüeke,Ziad A. Massy +10 more
TL;DR: Despite no change in serum C-reactive protein, the endotoxin-lowering effect of sevelamer may help to attenuate the inflammatory status of patients with chronic kidney disease and neither agent reduced circulating uremic toxins of high-molecular-weight or protein-bound toxins.
Journal ArticleDOI
Dialysis-associated amyloidosis.
TL;DR: Because dialysis technology has progressed considerably during the last decade, a significant beta 2-M removal can be achieved at present using high-flux dialyzers and a marked reduction in bioincompatibility during the dialysis procedure as manifested by activation of complement and stimulation of mononuclear blood cells can now be attained.